ClinicalTrials.gg
RecruitingNCT03571763Updated Apr 27, 2026

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

An observational study in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by General Hospital of Shenyang Military Region · Observational

How we know

From the registry’s dates

  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,875
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.

Started
2018
with 4 others
Observational
7 of 34
3 open now
Primary completion
2026-12
later than 1 of 15 live
Registered
5th of 34
by date

Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is one of 5 that started in 2018, is one of 7 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 5th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, or all of them as a file.
02

Study summary

The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.

Read the detailed description

Cerebral microbleeds(CMBs) is a subclinical lesion caused by microvascular disease in the brain, characterized by microleakage of blood. About 30% of ischemic stroke patients, 40% of the healthy people over 80 years old, and 60% of intracranial hemorrhage patients have microbleeds. With the development of imaging technology, clinically more and more patients have found microbleeds in the brain. How these patients are treated with antithrombotic drugs is not yet clear and is in urgent need of evidence. There are only a few prospective cohort studies to determine whether antithrombotic therapy increases the risk of intracranial hemorrhage in ischemic stroke patients with CMBs, but the results are uncertain. More importantly, whether antithrombotic therapy increases the incidence of the emerging CMBs, and whether the change of increased microbleeds is associated with increased intracranial hemorrhage has not been reported.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Cerebral Hemorrhage
  • anti-thrombosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ischemic stroke patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age ≥18 years;
  2. Acute ischemic stroke patient confirmed by imaging;
  3. Time of onset: within 3 months;
  4. Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
  5. Baseline SWI sequence must have at least one CMB ;
  6. NIHSS≤10

Exclusion criteria

Exclusion Criteria:

  1. MRI ;
  2. Hemorrhagic transformation after acute Ischemic stroke;
  3. Contraindication for antiplatelet or anticoagulation therapy;
  4. Severe head trauma or intracranial hemorrhage occurred in the past six months;
  5. obvious coagulopathy;
  6. Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);
  7. other unqualified patients judged by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,875 participants (estimated)
Patient registry
No

Groups and cohorts

  • acute ischemic stroke patient

    acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months

    Other: SWI sequence

Interventions

  • OtherSWI sequence

    Acute ischemic stroke patient confirmed by SWI sequence

06

What researchers measure

Primary outcomes

  1. all cerebral bleeding events

    incidence of both cerebral microbleeds and intracranial hemorrhage, determined by MRI

    Time frame: 360 days

Secondary outcomes

  1. all cerebral bleeding events

    incidence of both cerebral microbleeds and intracranial hemorrhage, determined by MRI

    Time frame: 180 days

  2. proportion of mRS 0-1.

    the minimum and maximum values of modified Rankin Score (mRS) are 0 and 6, respectively; higher score mean a worse outcome

    Time frame: 180、360 days

  3. proportion of cerebral microbleeds

    cerebral microbleeds, determined by MRI

    Time frame: 180 、360 days

  4. proportion of cerebral hemorrhage

    cerebral hemorrhage, determined by MRI

    Time frame: 180、360 days

  5. the occurence of stroke or other vascular events

    Time frame: 180、360 days

  6. the occurence of death due to any cause

    Time frame: 180、360 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Dec 2026, 100 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 100 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 28, 2018
StartActual
Aug 1, 2018
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03571763
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director of neurological department, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Jun 28, 2018
Start date
Aug 1, 2018
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

chen huisheng, doctor
Contact
chszh@aliyun.com
86-24-28897511
wang xinhong, doctor
Contact
450341972@qq.com
15309885658
chen huisheng, doctor
study director · General Hospital of Shenyang Military Region

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion